
|Articles|September 25, 2014
- Gynecologic Cancers (Issue 1)
- Volume 1
- Issue 1
Trabectedin as a Treatment Option for Patients with Ovarian Cancer
Author(s)Bradley Monk, MD
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses trabectedin as a potential agent to treat ovarian cancer.
Advertisement
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses trabectedin as a potential agent to treat ovarian cancer.
Read about research into ovarian cancer > >
Articles in this issue
about 11 years ago
The Role of Molecular Testing in Gynecologic Cancersabout 11 years ago
Dream Team Aims To Change the Face of Ovarian Cancer Researchabout 11 years ago
On The Horizon for Ovarian Cancer: Potentially Promising Treatmentsabout 11 years ago
Cediranib Versus Olaparib in Recurrent Platinum-Sensitive Ovarian CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5









































